Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Bayer Buys Dihon, a China OTC/TCM Pharma

publication date: Feb 27, 2014
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Bayer AG will acquire Dihon Pharmaceutical Group of China, a privately held company that makes OTC and TCM products. Bayer said Dihon had revenues of $168 million in 2013. Analysts estimated Bayer may have paid as much as $680 million for its latest acquisition, though the purchase price was not disclosed. Dihon is located in southwest China’s Yunnan province. More details....

Stock Symbol: (XETRA: BAYN)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at this event:
 
 
Hope to see you there!
 
ChinaBio® Events
 
China Forum 2014

Frankfurt, Germany
November 2, 2014

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors